

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) on voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group has been notified by the Ministry of Industry and Information Technology of the People’s Republic of China, Consumption Division* (the “**MIIT, Consumption Division**”) (中華人民共和國工業和信息化部消費品司), the Chongqing Commission of Economy and Informatization* (重慶市經濟和信息化委員會) and the Chongqing Changshou District Commission of Economy and Informatization* (重慶市長壽區經濟和信息化委員會) that Chloroquine Phosphate (磷酸氯喹) has been tested and proved to have certain curative effect in combating against the Pneumonia infected by Novel Coronavirus (新型冠狀病毒感染的肺炎) (the “**2019-nCoV**”).

Chongqing Kangle Pharmaceutical Co., Ltd.* (重慶康樂製藥有限公司) (“**Chongqing Kangle**”), being an indirect non-wholly owned subsidiary of the Company, had previously been accredited by the National Medical Products Administration, previously known as the China Food and Drug Administration (國家藥品監督管理局 (前稱國家食品藥品監督管理總局)), to manufacture the Active Pharmaceutical Ingredients Chloroquine Phosphate (原料藥磷酸氯喹). In view of certain curative effect against the 2019-nCoV, Chongqing Kangle has been requested by the MIIT, Consumption Division to promptly resume the manufacturing and production of the Active Pharmaceutical Ingredients Chloroquine Phosphate. Due to the outbreak of the 2019-nCoV, the Leading Group for 2019-nCoV Prevention and Control Work of Changshou District, Chongqing* (重慶市長壽區新型冠狀病毒感染的肺炎防控工作領導小組) ordered the enterprises in that district not to resume work prior to 10 February 2020 in principle, with the exception of industries necessary for the prevention and control of epidemic, the living of people and the operation of city. Chongqing Kangle has been requested to resume work earlier than the said day promptly. The Group has further been notified that the Active Pharmaceutical Ingredients Chloroquine Phosphate, which is accredited to be manufactured by Chongqing Kangle, has just been included in the list of central medical reserve (中央醫藥儲備) of the People’s Republic of China.

As at the date of this announcement, the manufacturing and production of the Active Pharmaceutical Ingredients Chloroquine Phosphate by Chongqing Kangle has been resumed. The Board would like to thank for the accreditation of the Group's ability to manufacture pharmaceutical products and will lead the Group to make every effort and contribution to combat against the 2019-nCoV.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 3 February 2020

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.

* *For identification purposes only*